Understanding how proteins can predict blood pressure response in hypertensive patients undergoing renal denervation.
The Predictive Role of Proteomics in Blood Pressure Response of Hypertensive Patients Undergoing Renal Denervation.
This study is testing if certain proteins in urine can help predict how well blood pressure will respond to a treatment called renal denervation in people with high blood pressure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Hippocration General Hospital Academic / other |
| Locations | 1 site (Athens) |
| Trial ID | NCT06208501 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of proteomics in predicting blood pressure responses in hypertensive patients who are undergoing renal denervation, a minimally invasive procedure aimed at disrupting renal sympathetic nerves. The study aims to identify biomarkers that can reliably indicate which patients are likely to benefit from this treatment, as current response rates vary significantly. Patients will be monitored through urine samples for proteomic analysis and blood pressure measurements using both office and ambulatory methods. The goal is to enhance therapeutic outcomes by tailoring treatment based on individual biomarker profiles.
Who should consider this trial
Good fit: Ideal candidates for this study are hypertensive patients aged 18-80 who have been on standard antihypertensive medications for at least 8 weeks and have elevated blood pressure readings.
Not a fit: Patients with renal artery abnormalities, secondary hypertension, or those with certain comorbidities such as active cancer or severe renal impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for hypertension, improving blood pressure control in patients undergoing renal denervation.
How similar studies have performed: While renal denervation has shown variable success in previous studies, this approach of using proteomics to predict treatment response is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All treated patients have to be on standard antihypertensive regimens for at least 8 weeks * Age 18-80 years * Office systolic blood pressure ≥140 mmHg and * Ambulatory systolic blood pressure ≥130 mmHg Exclusion Criteria: * eGFR \<45mL/min/1.73m2 * Renal artery abnormalities * Type I diabetes mellitus * Secondary hypertension * Pregnant or breastfeeding women * Psychiatric or neurological disease which does not allow adequate co-operation * Active cancer on treatment
Where this trial is running
Athens
- First Cardiology Clinic, Hippokration General Hospital, National and Kapodistrian University of Athens — Athens, Greece (Recruiting)
Study contacts
- Study coordinator: Konstantinos P Tsioufis, Professor of Cardiology
- Email: ktsioufis@hippocratio.gr
- Phone: 2132088099
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.